Ken Griffin Tyra Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,500 shares of TYRA stock, worth $365,190. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,500
Previous 216,136
89.13%
Holding current value
$365,190
Previous $2.07 Million
84.14%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding TYRA
# of Institutions
115Shares Held
58.4MCall Options Held
23.5KPut Options Held
0-
Ra Capital Management, L.P. Boston, MA12.2MShares$190 Million2.93% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY4.08MShares$63.4 Million95.15% of portfolio
-
Nextech Invest, Ltd. Zurich, V84.06MShares$63 Million8.64% of portfolio
-
Nextech Invest Ag4.06MShares$63 Million10.51% of portfolio
-
Bvf Inc San Francisco, CA3.65MShares$56.7 Million2.76% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $652M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...